DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A self-expanding metal stent for complicated variceal hemorrhage: experience at a single center.

Author(s): Wright G, Lewis H, Hogan B, Burroughs A, Patch D, O'Beirne J

Affiliation(s): Sheila Sherlock Liver Centre, Royal Free Hospital, London, United Kingdom.

Publication date & source: 2010-01, Gastrointest Endosc., 71(1):71-8. Epub 2009 Oct 30.

BACKGROUND: Refractory variceal bleeding is associated with a high mortality. Existing salvage techniques such as transjugular intrahepatic portosystemic shunt (TIPS) and balloon tamponade (BT) have important limitations and may not be appropriate for all patients. OBJECTIVE: To evaluate the safety and efficacy of a novel removable self-expanding metal stent in the management of refractory variceal bleeding. DESIGN: Case series. SETTING: Tertiary referral liver center. PATIENTS: Ten patients with variceal hemorrhage with contraindications to TIPS insertion or BT. INTERVENTIONS: Insertion of a self-expanding metal stent (SX-Ella DANIS stent). MAIN OUTCOME MEASURES: Survival, failure to control bleeding, and complications. RESULTS: Stent insertion was successful in 9 of 10 patients. Failure to control bleeding was observed in 3 patients (2 with gastric varices), with control of bleeding in the remainder. Overall survival at 42 days was 50%. Six patients survived the acute bleeding episode and had stents removed endoscopically at a median of 9 days after insertion. One patient had a minor ulceration of the esophagus caused by stent insertion. CONCLUSIONS: Insertion of the SX-Ella DANIS stent in patients with refractory variceal bleeding or complications of previous therapy is effective for the control of bleeding. Stent insertion can be achieved in the majority of patients without fluoroscopic control and without major complications. In selected patients, SX-Ella DANIS stent insertion offers an alternative to other methods of salvage such as BT and TIPS and could be considered a substitute for BT after a prospective trial. 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017